Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gas-trointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogene-ity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immuno-logical, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.

Privitera, G., Pugliese, D., Rapaccini, G. L., Gasbarrini, A., Armuzzi, A., Guidi, L., Predictors and early markers of response to biological therapies in inflammatory bowel diseases, <<JOURNAL OF CLINICAL MEDICINE>>, n/a; 10 (4): 1-21. [doi:10.3390/jcm10040853] [http://hdl.handle.net/10807/204311]

Predictors and early markers of response to biological therapies in inflammatory bowel diseases

Privitera, Giuseppe;Pugliese, Daniela;Rapaccini, Gian Ludovico;Gasbarrini, Antonio;Armuzzi, Alessandro;Guidi, Luisa
2021

Abstract

Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gas-trointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogene-ity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immuno-logical, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.
2021
Inglese
Privitera, G., Pugliese, D., Rapaccini, G. L., Gasbarrini, A., Armuzzi, A., Guidi, L., Predictors and early markers of response to biological therapies in inflammatory bowel diseases, <<JOURNAL OF CLINICAL MEDICINE>>, n/a; 10 (4): 1-21. [doi:10.3390/jcm10040853] [http://hdl.handle.net/10807/204311]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/204311
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 17
social impact